Trial Review

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT03941509




Registration number
NCT03941509
Ethics application status
Date submitted
6/05/2019
Date registered
8/05/2019
Date last updated
13/01/2022

Titles & IDs
Public title
Nurse-led Antimicrobial Stewardship Intervention to Increase Antibiotic Appropriateness in Residential Aged Care Facilities
Scientific title
Stepped-wedge Cluster Randomised Controlled Trial to Increase Antibiotic Appropriateness in Residential Aged Care Facilities: a Nurse-led Bundled Antimicrobial Stewardship Intervention.
Secondary ID [1] 0 0
591/18
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Antimicrobial Stewardship 0 0
Urinary Tract Infections 0 0
Respiratory Tract Infections 0 0
Skin and Soft Tissue Infections 0 0
Condition category
Condition code
Infection 0 0 0 0
Studies of infection and infectious agents
Infection 0 0 0 0
Other infectious diseases
Infection 0 0 0 0
Sexually transmitted infections
Respiratory 0 0 0 0
Other respiratory disorders / diseases

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
BEHAVIORAL - Antimicrobial stewardship

No intervention: Control - All facilities will receive usual care during the control phase of the trial.

Experimental: Antimicrobial stewardship - Implementation of the nurse-led bundled antimicrobial stewardship intervention


BEHAVIORAL: Antimicrobial stewardship
Education, guidelines, communication tools and audit and feedback
Intervention code [1] 0 0
BEHAVIORAL
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Cumulative proportion of residents prescribed a systemic antimicrobial
Timepoint [1] 0 0
Assessed from commencement of the intervention at each facility until the conclusion of the trial at 16 months
Primary outcome [2] 0 0
Rate of total days of systemic antimicrobial therapy per 1,000 occupied bed days (OBD)
Timepoint [2] 0 0
Assessed from commencement of the intervention at each facility until the conclusion of the trial at 16 months
Secondary outcome [1] 0 0
Number of courses of systemic antimicrobial therapy per 1,000 OBD.
Timepoint [1] 0 0
Assessed from commencement of the intervention at each facility until the conclusion of the trial at 16 months
Secondary outcome [2] 0 0
Proportion of appropriate antimicrobial use.
Timepoint [2] 0 0
Assessed from commencement of the intervention at each facility until the conclusion of the trial at 16 months
Secondary outcome [3] 0 0
Frequency of carriage of antimicrobial-resistant organisms
Timepoint [3] 0 0
Assessed over a 12-month period during the trial (at least 2 months pre-intervention and 2 months post-intervention).
Secondary outcome [4] 0 0
Rate of Clostridium Difficile infection
Timepoint [4] 0 0
Assessed from commencement of the intervention at each facility until the conclusion of the trial at 16 months
Secondary outcome [5] 0 0
Change in facility-level antimicrobial susceptibility profile
Timepoint [5] 0 0
Assessed over a 12-month period during the trial (at least 2 months pre-intervention and 2 months post-intervention).
Secondary outcome [6] 0 0
Incidence of resident transfer to hospital for infectious indications
Timepoint [6] 0 0
Assessed from commencement of the intervention at each facility until the conclusion of the trial at 16 months
Secondary outcome [7] 0 0
All-cause mortality
Timepoint [7] 0 0
Assessed from commencement of the intervention at each facility until the conclusion of the trial at 16 months
Secondary outcome [8] 0 0
Perceptions from stakeholders on quality and uptake of the intervention
Timepoint [8] 0 0
Assessed at the conclusion of the trial at 16 months

Eligibility
Key inclusion criteria
Residents:

* All residents from 12 RACFs will have de-identified data collected including antimicrobial use, infection, hospitalisation and mortality.
* Residents or their guardians who provide informed consent to monthly biospecimen sampling and participation in one-on-one interviews or focus groups.

Health professionals:

- Health professionals (including aged care staff and GPs) who provide informed consent to participate in one-on-one interviews or focus groups.
Minimum age
No limit
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
* Residents or their guardians who do not consent to biospecimen sampling and/or participation in interviews/focus groups.
* Health professionals who do not consent to participate in interviews/focus groups.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Crossover
Other design features
Phase
NA
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
UNKNOWN
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
1/01/2021
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
1/06/2022
Actual
Sample size
Target
700
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
VIC
Recruitment hospital [1] 0 0
Bupa residential aged care facilities - Melbourne
Recruitment postcode(s) [1] 0 0
- Melbourne

Funding & Sponsors
Primary sponsor type
Government body
Name
Bayside Health
Address
Country
Other collaborator category [1] 0 0
Other
Name [1] 0 0
Bupa Aged Care Australia
Address [1] 0 0
Country [1] 0 0
Other collaborator category [2] 0 0
Other
Name [2] 0 0
Monash University
Address [2] 0 0
Country [2] 0 0

Ethics approval
Ethics application status

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Anton Peleg, MBBS, PhD, FRACP, PhD
Address 0 0
Monash University
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Natali Jokanovic, BPharm, PhD
Address 0 0
Country 0 0
Phone 0 0
+61 3 9903 0087
Fax 0 0
Email 0 0
[email protected]
Contact person for scientific queries

No information has been provided regarding IPD availability


What supporting documents are/will be available?

No Supporting Document Provided



Results publications and other study-related documents

No documents have been uploaded by study researchers.

Results not provided in https://clinicaltrials.gov/study/NCT03941509